c-peptide and MELAS-Syndrome

c-peptide has been researched along with MELAS-Syndrome* in 3 studies

Trials

1 trial(s) available for c-peptide and MELAS-Syndrome

ArticleYear
Pancreatic beta-cell secretory defect associated with mitochondrial point mutation of the tRNA(LEU(UUR)) gene: a study in seven families with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS).
    Diabetologia, 1994, Volume: 37, Issue:8

    Recent evidence suggests possible linkage between diabetes mellitus and mitochondrial gene mutation. We surveyed mitochondrial tRNA(LEU(UUR)) (3243) mutation in 7 mitochondrial encephalomyopathy, lactic acidosis and stroke-like episode (MELAS) families and identified 24 mutated subjects (7 MELAS probands and 17 non-MELAS relatives) as well as 11 non-mutant family members. An OGTT in the 24 mutant relatives revealed 14 diabetic subjects, 3 with impaired glucose tolerance and 7 with normal glucose tolerance and all non-mutant family members as having normal glucose tolerance. Insulinogenic index was significantly reduced in the mutant diabetic subjects and those with impaired and normal glucose tolerance in comparison with the normal control subjects and the non-mutant members. Urinary 24-h C-peptide immunoreactivity excretion was markedly reduced in the mutant diabetic subjects and those with normal and impaired glucose tolerance, compared with the control subjects and the non-mutant family members. Plasma C-peptide immunoreactivity 6 min after glucagon injection was markedly reduced in the mutant diabetic subjects and those with normal and impaired glucose tolerance compared with the control subjects and the non-mutant family members. Si, an index of insulin sensitivity of the four mutant subjects was within normal range. Islet cell antibodies were negative in sera of eight mutated diabetic subjects, 2 and 6 with impaired and normal glucose tolerance, respectively. Diabetic retinopathy and nephropathy were demonstrated in 7 (50%) and 12 (85.7%) of 14 mutant diabetic subjects, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: Adolescent; Adult; Aged; Base Sequence; C-Peptide; Child; Diabetes Mellitus; DNA Primers; DNA, Mitochondrial; Female; Humans; Islets of Langerhans; Male; MELAS Syndrome; Middle Aged; Mitochondria; Molecular Sequence Data; Pedigree; Point Mutation; Polymerase Chain Reaction; Reference Values; RNA, Transfer, Leu

1994

Other Studies

2 other study(ies) available for c-peptide and MELAS-Syndrome

ArticleYear
Correction of pancreatic beta-cell dysfunction with coenzyme Q(10) in a patient with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome and diabetes mellitus.
    European neurology, 2000, Volume: 43, Issue:1

    Topics: Adult; C-Peptide; Diabetes Complications; Female; Gene Expression; Humans; Islets of Langerhans; MELAS Syndrome; Pancreatic Diseases; Point Mutation; Ubiquinone

2000
Diabetes mellitus carrying a mutation in the mitochondrial tRNA(Leu(UUR)) gene.
    Diabetologia, 1995, Volume: 38, Issue:2

    We screened 214 Japanese NIDDM (non-insulin-dependent) diabetic patients with a family history of diabetes for mutations in the mitochondrial tRNA(Leu(UUR)) gene using polymerase chain reaction-restriction fragment length polymorphism and direct sequencing. Six patients were identified as having an A to G transition at position 3243 (3243 mutation), but no patients were detected with a T to C transition at position 3271, in the mitochondrial tRNA(Leu(UUR)) gene. These two mutations were not present in 85 healthy control subjects. It was disclosed that the patients' mothers were also affected by diabetes mellitus in five of the six cases. In these six affected patients, the 3243 mutation shows variable phenotypes, such as the degree of multiple organ involvement, intrafamilial and interfamilial differences in disease characteristics, and the degree of the involvement of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) phenotype. Endocrinological examinations revealed that those diabetic patients with the 3243 mutation show not only beta-cell dysfunction, but also a defect in alpha-cell function, which is considered characteristic of diabetes with the 3243 mutation. When compared with 50 selected diabetic control subjects without the 3243 mutation, whose mothers, but not fathers, were found to have diabetes, it was established statistically that those with the 3243 mutation possess the following clinical characteristics; 1) the age of diabetes onset is lower, 2) they have lean body constitutions, and 3) they are more likely to be treated with insulin than control subjects. We suggest that diabetes with the 3243 mutation possesses phenotypes distinct from those in common forms of diabetes.

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Base Sequence; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Genetic Variation; Glucagon; Humans; Male; MELAS Syndrome; Middle Aged; Mitochondria; Molecular Sequence Data; Pedigree; Point Mutation; Polymorphism, Restriction Fragment Length; RNA, Transfer, Leu

1995